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Abstract: Behçet syndrome (BS) is a multisystem vasculitis with unknown etiology and a unique 
geographic distribution. The disease course is char
abating as the years pass. The usual onset is in the third decade. Recurrent skin mucosa lesions and 
sight threatening panuveitis are the hallmark of the disease. 
females. Vascular involvement can occur in up to 40
in that it may involve all sizes and types of vessels. It affects the veins more than the arteries. Lower 
extremity vein thrombosis is the most frequent manifestati
vena  cava  thrombosis,  pulmonary  artery  aneurysms,  Budd
aneurysms,  dural  sinus  thrombosis  and  abdominal  aorta  aneurysms.  Vascular  involvement  is 
frequently associated with constituti
major  cause  of  increased  mortality.  A  predominantly  neutrophilic  vasculitis  around  the  vaso 
vasorum  is  typical  of  BS.  The  thrombus  is  tightly  adherent  to  the  vessel  wall  which  probably 
explains  why  thromboembolism  is  so  rare  despite  the  high  frequency  of  venous  disease. 
Thrombophilic  factors  do  not  seem  to  explain  thrombotic  tendency  in  BS.  Immunosuppressive 
treatment is essential in suppression and preventing the attacks.
 
Introduction: We herein give first a general outline of 
Behçet’s syndrome (BS), then review the available data 
on the vascular part of the disease, and finally discuss 
the relative absence of embolic phenomena in spite of 
the  high  frequency  of  thrombotic  episodes  in  this 
disorder in the Management section.  
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Behçet syndrome (BS) is a multisystem vasculitis with unknown etiology and a unique 
geographic distribution. The disease course is characterized by exacerbations and remissions while 
abating as the years pass. The usual onset is in the third decade. Recurrent skin mucosa lesions and 
sight threatening panuveitis are the hallmark of the disease. Males are more severely affected than 
volvement can occur in up to 40% of cases. BS is unique among the vasculitides 
in that it may involve all sizes and types of vessels. It affects the veins more than the arteries. Lower 
extremity vein thrombosis is the most frequent manifestation of vascular involvement, followed by 
vena  cava  thrombosis,  pulmonary  artery  aneurysms,  Budd-Chiari  syndrome,  peripheral  artery 
aneurysms,  dural  sinus  thrombosis  and  abdominal  aorta  aneurysms.  Vascular  involvement  is 
frequently associated with constitutional symptoms and increased acute phase response and is the 
major  cause  of  increased  mortality.  A  predominantly  neutrophilic  vasculitis  around  the  vaso 
vasorum  is  typical  of  BS.  The  thrombus  is  tightly  adherent  to  the  vessel  wall  which  probably 
y  thromboembolism  is  so  rare  despite  the  high  frequency  of  venous  disease. 
Thrombophilic  factors  do  not  seem  to  explain  thrombotic  tendency  in  BS.  Immunosuppressive 
treatment is essential in suppression and preventing the attacks.     
erein give first a general outline of 
Behçet’s syndrome (BS), then review the available data 
on the vascular part of the disease, and finally discuss 
the relative absence of embolic phenomena in spite of 
the  high  frequency  of  thrombotic  episodes  in  this 
BS  is  named  after  Hulusi  Behçet,  a  Turkish 
dermatologist,  who  described  three  patients  with  a 
triple symptom complex of aphthae, genital ulcers, and 
hypopyon  uveitis  for  the  first  time  in  1937.
syndrome  is  characterized  by  recurrent  oral  aphthae 
which  is  the  sine  qua  non  and  other  recurrent 
manifestations  -in  order  of  decreasing  frequency
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genital  ulcers,  variable  skin  lesions,  arthritis,  uveitis 
and  thrombophlebitis.
2,3  BS  may  also  involve 
gastrointestinal  and  central  nervous  system.
2,3  It  is 
considered as a nonspecific systemic vasculitis of small 
and  large  vessels  involving  both  venous  and  arterial 
sides. The aetiopathogenesis is still unknown.
2-5 
BS has a distinct geographical distribution along the 
ancient  trading  route  known  as  the  ‘Silk  Route’, 
extending  from  the  Mediterranean  countries  to  Far 
East.  This  suggests  that  the  etiological  agent(s), 
including several genetic factors such as HLA-B51 had 
spread through this way.
6 The prevalence of BS was 
reported to be between 20 to 421 among 100,000 adult 
population in Turkey while this was 17 in Iraq and 120 
in  an  Arab  community  in  Israel.  The  estimated 
prevalence ranges are less in other part of the globe: 
0.64 in the UK, 6.4 in Spain, 7.1 in France, and 8.6 in 
the  USA  per  100,000.
7  Some  manifestations  of  the 
disease also show regional differences: gastrointestinal 
involvement is frequent in the Far East but infrequent 
in Turkey.
8 The positivity of pathergy test is frequent 
in endemic countries whereas less common in Europe 
and  the  USA.
9  Finally,  the  most  consistent  genetic 
marker, the HLA B51 association is more pronounced 
in the endemic areas as well.
7 
The  usual  onset  of  the  syndrome  is  in  the  third 
decade. The onset is rare among the aged over 50 years 
and in the childhood. While both genders are equally 
affected  the  syndrome  runs  a  more  severe  disease 
course among men and the young.
10,11 
A  set  of  diagnostic  (classification)  criteria  was 
published  in  1990  by  International  Study  Group.
12 
These criteria define oral ulceration as the sine qua non 
and additionally require two other organ involvements 
for the diagnosis, as shown in Table 1. 
 
Clinical  Manifestations:  Clinical  manifestations  are 
variable and characterized by unpredictable periods of 
recurrences  and  remissions.  Mucocutaneous  features 
are the most common and the presenting symptoms of 
the  disease  whereas  eye,  vascular  and  neurological 
involvement are the most serious ones.  
 
Mucocutaneous  Findings:  Oral  ulcerations  are 
frequently  the  first  as  well  as  the  most  frequent 
symptoms.  Minor  aphthous  ulcers  (<10mm  in 
diameter)  are  the  most  common  type.  Aphthae  are 
usually multiple and occur more frequently in BS but it 
is difficult to distinguish them from those of recurrent 
oral ulcers due to other causes.  
Genital ulcers usually occur on the scrotum but are 
infrequent on the shaft or on the glans penis in males. 
Urethritis or dysuria is not a part of BS. Both major 
and  minor  labia  are  affected  in  the  female.  Genital 
ulcers affect the quality of life. The big ulcers usually 
heal  with  scarring,  which  is  useful  in  differential 
diagnosis.
13 
Acne-like  lesions  or  papulo-pustular  lesions  are 
seen  both  at  the  usual  acne  sites  as  well  as  at 
uncommon sites such as upper extremities and are also 
indistinguishable  from  acne  vulgaris  by  both  in 
appearance  and  pathologically.
14  Nodular  lesions  are 
observed  in  50  %  of  the  patients  and  are  usually 
confined  to  lower  limbs.  Erythema  nodosum  can  be 
difficult  to  distinguish  from  superficial 
thrombophlebitis with the naked eye.  
The  pathergy  reaction  is  a  non-specific 
hyperreactivity of the skin to trauma such as a needle 
prick.  A  papule  or  pustule  typically  forms  in  24-48 
hours after a skin puncture with a needle. This is quite 
specific to Behçet’s patients.
15 While the positivity in 
60-70%  of  patients  in  Turkey  and  Japan  it  is  rarely 
observed  in  patients  with  BS  from  Northern  Europe 
and North America.
9 
Extra-genital ulcers, Sweet’s syndrome,  pyoderma 
gangrenosum,  leucocytoclastic  vasculitis  and  true 
arterial lesions are other less common skin lesions. 
 
Eye  Involvement:  A  chronic,  relapsing  bilateral 
uveitis involving both anterior and posterior chambers 
are seen in half of all patients but is more frequent and 
more severe among the male and the young. Anterior 
uveitis with intense inflammation (hypopyon) observed 
in  only  a  small  fraction  of  patients  indicates  a  bad 
outcome and is generally associated with severe retinal 
vasculitis.  Posterior  uveal  inflammation  with 
involvement of the retina can cause retinal exudates, 
haemorrhages,  venous  thrombosis,  papilloedema  and 
macular  disease.  Recurrent  attacks  of  eye  disease 




Musculoskeletal  System:  Joint  involvement  is 
observed in half of the patients. Arthritis is usually a 
non- deforming and non-erosive mono- or oligoarthritis 
resolving  in  a  few  weeks.  The  most  frequently 
involved  joints  are  knees,  followed  by  ankles,  wrist, 
and  elbows.
17  Back  pain  is  rare  and  sacroiliac  joint 
involvement is not part of the disease.
18 Patients with 
BS  and  arthritis  also  have  more  acne  lesions.
19 
Furthermore, patients with arthritis and acnea lesions 
have  a  significantly  more  entesopathy  scores.
20 
Synovial  fluid  is  commonly  inflammatory  but  has  a 
good mucin clot. Myositis can be seen rarely.  
 
Central  Nervous  System:  Central  nervous  system 
(CNS) disease occurs in 5-10 % of patients in the form 
of either parenchymal brain involvement (80 %) or in 
the form of non-parenchymal disease (20%) which is 
manifested  as  dural  sinus  thrombosis  or  intracranialMediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
 
Table 1. International Study Group Criteria for the Diagnosis of Behçet’s Syndrome 
Criterion  Definition 
Recurrent oral ulceration  Aphthous or herpetiform lesions; observed by the physician or patient; recurring at least 3 times a year. 
Recurrent genital ulceration  Aphthous ulceration or scarring observed by the physician or reliably described by the patient. 
Eye lesions 
Anterior or posterior uveitis or cells in the vitreus body on slit –lamp examination or retinal vasculitis 
detected by an ophthalmologist. 
Skin lesions 
Erythema nodosum, pseudofolliculitis, papulopustular lesions or acneiform nodules, not related to 
glucocorticoids treatment or adolescence.  
Positive pathergy test  Test interpreted as positive by the physician at 24-48 h. 
 
hypertension.  Brainstem  involvement  is  the  most 
characteristic type of involvement in the parenchymal 
type, while spinal cord and hemispheric involvement 
are  rarely  observed.  Pyramidal  signs,  hemiparesis, 
behavioral  –cognitive  changes  and  sphincter 
disturbances  and/or  impotence  are  the  main  clinical 
manifestations.  Psychiatric  problems  may  develop  in 
some  patients.  Peripheral  neuropathy  is  rare.  A  high 
protein or cell count in cerebrospinal fluid examination 
implies  a  grave  prognosis.  On  the  other  hand,  non-
parenchymal  type  of  involvement  -  which  will  be 
discussed in detail in the vascular section - is presented 
mainly  with  symptoms  of  increased  intracranial 
pressure  symptoms  such  as  severe  headache, 
papilloedema and motor ocular nerve palsies.
21,22 Dural 
sinus thrombosis has relatively benign prognosis.  
 
Gastrointestinal  Involvement:  Gastrointestinal 
involvement  occurs  in  one-third  of  patients  from 
Japan
23 but it is quite rare in Turkey.
8 The symptoms 
resemble  to  those  of  inflammatory  bowel  diseases. 
Mucosal ulceration is found in the ileum, the caecum 
and the colon.
24 Hepatic problems are not common in 
BS  unless  an  associated  Budd-Chiari  syndrome  is 
present.
25 
Other  uncommon  clinical  manifestations  are 
glomerulonephritis,  amyloidosis  of  the  AA  type, 
voiding dysfunction due to direct bladder involvement, 
and epididymitis. 
 
Vascular Involvement: Vascular disease is seen in up 
to 40 % of the patients and as seen in all major organ 
involvement it has a definite male preponderance.
11,26 
Venous  involvement  is  more  common  than  arterial 
disease  (75  %  vs  25  %).
11,26  Lower  extremity  vein 
thrombosis (LEVT) is the most frequent manifestation 
of  vascular  involvement.
11,26  Vena  cava  thrombosis, 
pulmonary  artery  aneurysms  (PAA),  Budd-Chiari 
syndrome,  peripheral  artery  aneurysms,  dural  sinus 
thrombosis  and  abdominal  aorta  aneurysms  were  the 
other  vascular  manifestations  as  listed  in  order  of 
decreasing frequency.
26 Table 2 defines various forms 
of  vascular  involvement  in  BS.  Arterial  disease  is 
manifested  mostly  in  the  form  of  aneurysms.
11,26,  27 
Arterial  occlusions  are  seldom  seen  and  reported  to 




Table  2.  Various  forms  of  vascular  involvement  in  Behçet’s 
syndrome 
1.  Deep vein thrombosis of lower extremities 
a.  Femoral with or without iliac vein 
b.  Popliteal vein  
c.  Crural vein 
2.  Superficial thrombophlebitis  
a.  Greater saphenous vein 
b.  Lesser saphenous vein 
3.  Superior vena cava syndrome 
4.  Inferior vena cava syndrome 
5.  Cerebral venous sinus thrombosis 
6.  Budd-Chiari syndrome 
7.  Abdominal aortic aneurysm 
8.  Peripheral aneurysm 
a.  Femoral/Iliac  artery 
b.  Popliteal artery 
c.  Tibial artery 
d.  Radial artery 
9.  Carotid artery aneurysm 
10.  Pulmonary artery aneurysm/thrombosis 
11.  Other rare venous & arterial events  
a.  Brachial vein thrombosis 
b.  Portal vein thrombosis 
c.  Radial artery occlusion 
 
Vascular involvement is frequently associated with 
fever along with constitutional symptoms and manifest 
usually with high acute phase response. Furthermore, it 
causes  severe  morbidity  and  increased  mortality.
11 
PAA,  Budd-Chiari  syndrome  and  vena  cava 
thrombosis  especially  are  the  main  diseases  that  are 
associated with increased mortality.   
 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
Time to Occur: LEVT is an early finding occurring 
usually within the first few years of disease onset.
11,26 
Similarly,  PAA  and  Budd-Chiari  syndrome  are  also 
reported  to occur  early.
11,26,28 Dural sinus  thrombosis 
also seems to occur early since it is the most preferred 
manifestation  among  juvenile  BS  patients.
21,22,29 
However, vena cava thrombosis and aneurysms other 
than PAA are late findings.
11,26 We had reported that 
vena cava thrombosis develops in a median of 5 years 
whereas  abdominal  aorta  and  peripheral  arterial 
aneurysms develop in a median of 7 years.
11 
 
Types of involvement and clinical manifestations: 
a)  Lower  extremity  vein  thrombosis  (LEVT): 
Deep  veins  of  the  lower  extremity  are  the  most 
common sites of venous thrombosis, which constitute 
60-80 % of vascular lesions.
11,26,30-34 The affected veins 
in  descending  order  of  frequency  are  femoral 
(superficial, deep and common), popliteal, saphenous 
(magna  and  parva)  and  crural  veins.
35  Furthermore, 
chronic relapsing vein thromboses in the legs tend to 
precede  other  sites  of  major  vessel  involvement.
26 
LVET may cause erythema with induration (77%), leg 
pain (74 %), varicose veins (68%), edema (61%), skin 
hyperpigmentation  (58%),  intermittent  claudication 
(36%), and ulceration on the tibia or malleol (17%).
35 
Figure  1  and  2  show  two  BS  patients  with  chronic 
vein thrombosis in the lower extremities. Recently, we 
assessed  and  compared  clinical  and  radiologic 
characteristics  of  LVET  between  BS  and  non-BS 
patients.
35 The mean number of involved veins and the 
clinical severity score were higher among BS patients 
with  LVET  compared  to  non-BS  patients.
35 
Furthermore LVET tended to develop more bilaterally 
in BS patients compared to non-BS patients.
35 It seems 
that  venous  thrombophlebitis  and  thrombotic 
involvement run a slow and insidious course over time, 
since  many  patients  recall  only  one  or  two  venous 
overt  attacks  in  the  legs,  despite  the  radiological 
evidence of extensive progression of venous disease.
35 
Among  the  above  mentioned  clinical  symptoms, 
intermittent  claudication,  we  believe,  deserves  a  bit 
detailed explanation. It is usually a sign of peripheral 
arterial insufficiency which is most of the time due to 
atherosclerosis. However, the ‘claudication’ symptom 
which  we  persistently  find  to  be  increased  in  BS 
patients  with  LEVT
35,36  is  stemming  from  chronic 
thrombosis  of  iliac/femoral  veins  and  must  be 
described  in  fact  as  “venous  claudication”  which  is 
defined  by  several  authors  in  the  past  as  exercise 
related thigh or leg pain resulting from severe venous 
outflow impairment.
37 Moreover we and others showed 
that atherosclerosis was not increased in BS.
36,38-40 
b)  Superficial  thrombophlebitis:  Superficial 
thrombophlebitis  (STM)  tends  to  be  associated  with 
 
Figure 1. Chronic deep vein thrombosis on the lower extremity: 
Hyperpigmentation, edema,  varicose veins and a  mild induration 
with erythema are visible on the lower part of the tibia and foot.  
 
deep  vein  thrombosis  in  the  lower  extremity  and 
inferior vena cava.
41,42 It is manifested as red nodular 
lesions  that  mimic  erythema  nodosum.
3  While 
clinically  the  two  lesions  are  indistinguishable  from 
each  other  erythema  nodosum  is  more  common  in 
females  and  associated  usually  with  other 
mucocutaneous manifestations such as oral and genital 
ulcer.
42  On  the  other  hand  STM  lesions  are  more 
common  among  male  patients  and  associated  with 
large  vessel  involvement  elsewhere.
41,42  On  closer 
examination  STM  lesions  are  seen  as  string  –like 
lesions  following  vein  tracts.  Both  B-mode  and 
Doppler  dermal  ultrasonography  can  be  helpful  to 
differentiate between the two.
42 
 
Figure 2. Chronic vein thrombosis with stasis ulcer on the lower 
extremity: Large active ulcer on the medial lower part of the tibia is 
noted in addition to the severe induration, hyperpigmentation and 
varicose veins on the skin.  
 
STM  involve  large  and  small  veins  of  the  lower 
extremities,  major  saphenous  vein  being  mostly 
affected.  Histological  examination  reveals  organized 
thrombi in the lumen of the involved vein. On the other Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
hand septal pannuculitis with medium vessel vasculitis 
is frequently seen in the histopathology specimens of 
erythema nodosum.
43 
c)  Vena  cava  thrombosis:  Clinical  signs  vary 
according  to  the  anatomical  localization  of  the 
involvement. Chronic occlusion  of  the  caval  systems 
leads to the appearance of prominent venous collaterals 
on  the  thoracic  and  abdominal  walls  (Figure  3). 
Obstruction  of  inferior  vena  cava  (IVC)  may  cause 
venous claudication, crural ulcers, oesophageal varices, 
and  hyperpigmentation  on  the  skin  of  the  lower 
extremities.
26,30-34 Thrombotic involvement may extend 
from hepatic veins to femoral / iliac veins.
35 
 
Figure 3. Collaterals on the abdominal wall in a patient with vena 
cava  inferior  thrombosis  and  Budd-Chiari  syndrome.  Note  the 
profuse swelling and distention of the abdomen due to ascites.  
 
Superior  vena  cava  (SVC)  thrombosis  presents  with 
swelling  in  the  face  and  upper  extremities  with  full 
jugular  veins  without  pulsation  (Figure  4).
26,30-34 
Occasionally  patients  may  have  dyspnea  and  sleep 
apnea disorder. Lower extremity deep vein thrombosis 
is  less  common  than  in  patients  with  IVC  disease.
26 
Despite the alarming presentation, the SVC thrombosis 
in  BS  usually  has  a  benign  course  with  efficient 
collateral circulation.
44 It might rarely be complicated 
with pleural effusion and chylothorax.
44 
d)  Hepatic  veins:  Hepatic  vein  thrombosis  may 
cause  Budd-Chiari  syndrome  which  may  manifest 
clinically as abdominal pain, ascites, and edema on the 
scrotum and lower extremities (Figure 3). Liver failure 
may develop in severe cases. It is a rare complication 
of BS, but carries a high mortality rate. In one large 
series  from  Turkey  surveyed  by  Bayraktar  et  al,  the 
frequency  and  outcome  of  Budd-Chiari  syndrome  in 
493 patients with BS during a 8 year period from 1985 
to 1994 was studied.
28 BS was the single most frequent 
cause  of  Budd  Chiari  syndrome,  accounting  for 
roughly half of such patients.
28 There were 14 (26%) 
patients with Budd-Chiari syndrome out of 53 patients 
with large vessel thrombosis. Of these 14 patients 10 
(60%) died with a mean survival of 10 months.
28 In our 
20  year  survey  all  3  patients  with  Budd-Chiari 
syndrome had died during the follow-up.
11 
e)  Dural  sinus  thrombosis:  Thrombosis  of  the 
venous  sinuses  may  present  with  symptoms  of 
increased  intracranial  pressure  such  as  severe 
headache, papilloedema, sixth nerve palsy and rarely 
with  fever.  The  major  vessel  involvement  is  closely 
associated  with  dural  sinus  thrombi,  suggesting  that 
this type of neurological involvement is also part of the 
vascular spectrum.
45 Dural sinus thrombosis is also the 
predominant  type  of  neurological  involvement  in 
juvenile  BS  patients.
29  This  type  of  neurological 
involvement has a significantly favorable outcome than 
parenchymal type and is seen mostly in males.
21,22 
f)  Pulmonary  artery  involvement:  Pulmonary 
artery involvement (PAI) is uncommon with a reported 
prevalence  rate  of  less  than  5%.
46,47  PAI  is  mainly 
manifested by pulmonary artery aneurysms (PAA) and 
less  often  solely  by  ‘in  situ’  pulmonary  artery 
thrombosis  (PAT)  in  CT  images.
48  Thrombosis 
develops  usually  as  a  complication  to  underlying 
extensive vasculitis. Therefore we suppose that despite 
the  high  prevalence  of  venous  thrombosis  in  BS  as 
presented  earlier,  pulmonary  thromboembolism  is 
extremely rare in BS. Our clinical studies support this 
assumption  by  not  finding  any  pulmonary 
thromboembolism  case  among  BS  with  extensive 
venous  disease  when  followed  longitudinally  for  a 
substantial period of time.
11,26,35,46-48 Also, one Japanese 
study  investigated  autopsies of  the  170 patients  with 
BS  (122  M/  48  F)  and  found  no  single  case  with 
pulmonary thromboembolism.
49 On the other hand, ‘in 
situ’ PAT in BS has a similar clinical and prognostic 
picture compared to PAA.
48  
Patients  with  PAI  present  with  fever,  chest  pain, 
coughing,  dyspnea  and  hemoptysis.
48  It  is  always 
associated with high acute phase response.
48 PAA are 
observed  as  bilateral  or  unilateral  hilar  opacities  on
 
Figure  4.  Neck  collaterals  in  a  patient  with  vena  cava  superior 
thrombosis.  
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chest  X-ray  or  thorax  CT  scans.  Aneurysms  can  be 
partially  or  totally  thrombosed  in  about  third  of  the 
cases.
48  The  involvement  is  usually  bilateral  and 
confined to main, lobar or segment arteries.
47-48 Inferior 
lobes are mostly involved.
48 
PAI  causes  significant  morbidity  and 
mortality.
11,46,47  We  had  reported  in  1994  that  12 
patients with PAA out of 24 (all men) died a mean of 
10 months after the onset of haemoptysis.
46 A decade 
later in 2004, we updated the outcome of PAA with 26 
BS patients who had been followed between 1992 and 
2002.
47  There  were  significantly  less  deaths  (23%) 
during a mean of 4 years in the recent group attributed 
mainly to earlier recognition and prompt treatment.
47 
g) Peripheral  arteries:  Aortic  and  peripheral 
arterial  aneurysms  are  also  major  causes  of  death 
because of the risk of rupture. Twenty-four patients (all 
male) with either abdominal aorta or peripheral artery 
aneurysms were identified between 1977 and 1996 at 
the thoracic and cardiovascular surgery department of 
Cerrahpasa  Medical  Faculty  in  a  study  by  Tuzun  et 
al.
50  Mortality  was  reported  to  be  17%.
50  Mostly 
abdominal  aorta,  femoral,  iliac,  popliteal  and  carotid 
arteries  are  involved.
50  Clinical  signs  of  abdominal 
aortic  aneurysms  include  abdominal  or  back  pain. 
Peripheral aneurysms present with pulsatile masses in 
the extremities or the neck. Constitutional symptoms 
like low grade fever, loss of appetite or an increase in 
the acute phase response are additional signs.
50 
h) Intracardiac  thrombosis:  Intracardiac 
thrombosis is a rare finding in BS, reported mostly in 
case  reports.
51 It is strongly  associated  with vascular 
involvement elsewhere in the body, mostly with PAI.
51 
It is found more frequently  among young males and 
located  usually  in  the  right  side  of  the  heart,  right 
ventricle  being  the  most  common  place.
51  The 
thrombosis  was  reported  to  be  tightly  adhered  to 
underlying endocardium or myocardium.
51 Histological 
studies revealed that there was an organizing thrombus 
containing inflammatory cell infiltrates with or without 
involvement of underlying cardiac tissue.
51 
 
Histopathology  of  Vascular  Disease:  Vascular 
inflammation  is  diffuse  not  patchy,  involving  large 
segments of the vessel wall.
52 This is usually associated 
with superimposed thrombus.
52,53 Thrombus as a rule is 
tightly adherent to the vessel wall supposedly without a 
free  floating tail.
52  The  veins  in  dermis  and subcutis 
may  be  obliterated  with  organizing  thrombi.
53  A 
predominantly neutrophilic vasculitis around the vaso 
vasorum  is  typical  of  BS.
50,52,53  Other  than  that, 
vascular  walls  may  show  fibrous  thickening, 
accompanied by non-specific inflammatory infiltrate.
53 
Kobayashi et al reported that there were intact internal 
elastic  membrane  and  increased  expression  of  HLA-
DR  positive  cells  in  the  endothelium.
54  Tuzun  et  al 
however, reported that in addition to the inflammation 
around  the  vaso  vasorum,  there  were  severe  medial 
destruction  with  loss  of  elastic  and  muscle  fibers, 
disarray of the internal elastic membrane in the active 
stage and dense periadventitial fibrosis in the chronic 
stage.
50 He also observed reactive lymph nodes that are 




Coagulation Abnormality in BS: So far, none of the 
thrombophilic  factors  were  shown  to  be  associated 
with the thrombotic tendency observed in BS.
52,55-59 A 
defect in fibrinolysis was however suggested.
60,61 Gul 
et al previously reported that coagulation factor V gene 
G1691A mutation (factor V Leiden), could contribute 
to thrombotic complications in BS patients with deep 
vein  thrombosis.
62  However,  this  was  not 
confirmed.
56,63,64  The  current  data  indicates  that  the 
pathogenesis  of  thrombosis  in  BS  is  not  due  to  a 
coagulation abnormality.  
 
Management  of  Vascular  Disease:  The  role  of 
anticoagulation in deep vein thrombosis has not been 
evaluated  in  a  controlled  study.  However,  2 
retrospective  studies  showed  that  anti-coagulant 
treatment  is  ineffective  in  preventing  venous 
thrombosis.
65,66  One  study  from  Turkey,  investigated 
the long term course of deep vein thrombosis in 95 BS 
patients.
65 The recurrence was observed in 44 (46%) 
and  post-thrombotic  syndrome  in  21  (22%)  of  the 
patients. The risk for recurrent DVT and development 
of  the  post-thrombotic  syndrome  was  found  to  be 
significantly  reduced  in  patients  receiving 
immunosuppressant  drugs  (azathioprine  or 
cyclophosphamide) (OR= 0.3, 95% CI: 0.04-0.88, p = 
0.03, and OR = 0.2, 95% CI= 0.04- 0.88, p = 0.03, 
respectively), whereas, anticoagulants were not found 
to be effective (OR= 0.6, 95% CI: 0.19-1.9, p = 0.4).
65 
One  retrospective  Korean  study  compared 
anticoagulant and immunosuppressive treatment in 37 
BS patients with venous thrombosis (66). BS patients 
with  venous  thrombosis  were  divided  into  three 
groups:  one  group  (n  =  16)  received 
immunosuppressive therapy alone, another group (n = 
17)  received  immunosuppressant  and  anticoagulation 
combination  therapy,  and  the  third  group  (n  =  4) 
received  anticoagulation  therapy  only.  Recurrence  of 
venous  thrombosis  occurred  in  two  cases  in  the 
immunosuppressant  group  (12.5%),  one  case  in  the 
combination therapy group (5.9%), and three cases in 
the  anticoagulant  group  (75%).  No  significant 
difference  was  found  between  recurrence  in  the 
immunosuppressant  and  combination  therapy  groups. 
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is essential and that anticoagulation therapy might not 
be  required  for  the  treatment  of  deep  venous 
thrombosis associated with BS.
66  
Because of inefficacy of the anticoagulation shown 
in  these  two  retrospective  studies
65,66  and  due  to  the 
reasons that we discussed earlier [a. relative absence of 
embolic phenomena in spite of the thrombotic episodes 
in  our  clinical  experience  with  over  7000  patients 
during  30  years  and  in  the  large  Japanese  autopsy 
registry, b. sticky nature of thrombosis with no floating 
free  tail,  c.  absence  of  coagulation  abnormality,  d. 
strong association of life threatening PAA with deep 
vein  thrombosis  and  e.  the  effectiveness  of  
azathioprine in preventing thrombotic attacks based on 
the results observed in both azathioprine trials]
67,68 we 
prefer  not  to  anti-coagulate  BS  patients  with  venous 
thrombosis.  Our  general  approach  is  to  treat  these 
patients  with  immunosuppressive  agents.
69 
Furthermore,  experience  with  fibrinolytic  therapy  is 
scarce  and  has  also  been  unsuccessful.  Surgery  of 
venous thrombosis is not advocated.  
Arterial  aneurysms,  especially  pulmonary  arterial 
aneurysms carry a more severe prognosis than venous 
thrombosis.  They  can  rupture  or  fistulate  into  the 
bronchi causing massive hemoptysis and even death in 
about 23% of the cases.
46-48 We suggest monthly pulses 
of  cyclophosphamide  combined  with  1mg/kg  of 
prednisolone and tapering the prednisolone dose to <10 
mg/day  after  three  months.  Anticoagulation  is 
contraindicated  because  of  the  risk  of  bleeding.  Our 
experience  with  intra-arterial  embolisation  is  limited, 
however  should  be tried  in  treatment  resistant  cases. 
Surgical resection is also not successful as often PAA 
are multiple and located at different parts of the lungs. 
Aneurysms  of  the  peripheral  arteries  should  be 
corrected surgically although there is a recurrence rate 
of about 30%.
50 Ligations were defined as the preferred 
choice of surgical treatment for aneurysms localized in 
the  extremities  while,  abdominal  aortic  aneurysms 
were treated better with graft insertions.
50 It has been 
also  suggested  that  immunosuppressive  treatment 
should be given to prevent recurrences.  
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